Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
Investor's Business Daily on MSN7d
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH StudyAkero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
An Akero Therapeutics drug in development for the fatty liver disease MASH now has clinical trial results showing the experimental treatment reversed organ scarring, bringing patients back from an ...
We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
Akero Therapeutics (AKRO) stock soared 115% after the company reported positive long-term results from a Phase 2b study of ...
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...
In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback